Showing results (91-100 of 239) with videos related to
Sort By:
Pageof 24
Breast (Edinburgh, Scotland)|July 29, 2014
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study)Pierre Fumoleau, Kevin M Koch, Etienne Brain, et al.Breast (Edinburgh, Scotland)|May 26, 2020
A multi-stakeholder approach in optimising patients' needs in the benefit assessment process of new metastatic breast cancer treatmentsFatima Cardoso, Nils Wilking, Renato Bernardini, et al.Breast (Edinburgh, Scotland)|February 8, 2022
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trialPaul Cottu, Alistair Ring, Hikmat Abdel-Razeq, et al.Seminars in Oncology|January 10, 2006
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancerNicola Personeni, Alain Hendlisz, Julien Gallez, et al.Journal of the National Cancer Institute|August 7, 2009
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapyFatima Cardoso, Philippe L Bedard, Eric P Winer, et al.Breast (Edinburgh, Scotland)|October 2, 2012
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancerFatima Cardoso, Jean-Luc Canon, Dino Amadori, et al.Breast (Edinburgh, Scotland)|November 26, 2025
Ensuring access to multidisciplinary care in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 4)Shani Paluch-Shimon, Laura Biganzoli, Julie Torode, et al.Breast (Edinburgh, Scotland)|October 24, 2022
Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancerMatti Aapro, Fatima Cardoso, Giuseppe Curigliano, et al.European Journal of Cancer (Oxford, England : 1990)|November 28, 2007
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokineticsAhmad Awada, Fatima Cardoso, Christel Fontaine, et al.Breast (Edinburgh, Scotland)|February 20, 2026
Biomarker recall and understanding among people living with metastatic breast cancer - results from an international patient surveyEva Schumacher-Wulf, Lesley Fallowfield, Runcie C W Chidebe, et al.Pageof 24